64321-95-5

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-AMINO-3-TRIFLUOROMETHYLBENZOATE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be a key component in the development of new drugs, enhancing their efficacy and selectivity.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 2-AMINO-3-TRIFLUOROMETHYLBENZOATE is utilized as an intermediate in the production of agrochemicals. Its properties make it suitable for the synthesis of compounds that can be used in pest control and crop protection, contributing to increased agricultural productivity.
Used in Organic Synthesis:
METHYL 2-AMINO-3-TRIFLUOROMETHYLBENZOATE is used as a versatile building block in organic synthesis for creating a variety of organic compounds. Its reactivity and functional groups enable the formation of diverse chemical entities for research and industrial applications.

InChI:InChI=1/C9H8F3NO2/c1-15-8(14)5-3-2-4-6(7(5)13)9(10,11)12/h2-4H,13H2,1H3

Upstream product

• 67-56-1 methanol 
• 391-12-8 7-trifluoromethylisatin 
• 313-12-2 2-amino-3-(trifluoromethyl)benzoic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 887144-94-7 Togni's reagent II 
• 134-20-3 2-carbomethoxyaniline 

Downstream Products

• 1214362-28-3 methyl 2-bromo-3-(trifluoromethyl)benzoate 
• 177420-63-2 2-bromo-3-(trifluoromethyl)benzoic acid 

Relevant academic research and scientific papers

CHEMICAL COMPOUNDS

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.

INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA

Disclosed are methods, compounds, and compositions for treating infection by an Apicomplexan parasite that include administering a compound that selectively inactivates ornithine aminotransferase of the Apicomplexan parasite. Specifically, the methods, co

Visible-light-promoted radical C-H trifluoromethylation of free anilines

The trifluoromethyl-substituted anilines are biologically active compounds and useful building blocks. In this communication, we have developed the first visible-light-induced radical trifluoromethylation of free anilines with the commercially available and easily handled Togni reagent at room temperature. The resulting products were successfully transformed into a variety of valuable fluorine-containing molecules and heterocyclic compounds. This protocol provides an economical and powerful route to trifluoromethylated free anilines.

Preparation of alkyl anthranilates

Alkyl anthranilates are prepared by reacting an isatin with an alkanol and hydrogen peroxide in the presence of an alkali metal alkanolate. The alkyl anthranilates obtainable by the process of the invention are valuable starting materials for the prep

Quinoline-3-carboxamides

Novel quinoline-3-carboxamides of the formula STR1 wherein R1 is in the 5,6,7 or 8-position and is selected from the group consisting of hydrogen, halogen, --CF3, --OCF3, --SCF3, straight chain alkyl of 1 to 4 carbon atoms, branched alkyl of 3 to 5 carbon atoms and alkoxy of 1 to 4 carbon atoms, R2 is selected from the group consisting of hydrogen and methyl, R3 is selected from the group consisting of thiazolyl, 4,5-dihydrothiazolyl, pyridinyl, oxazolyl and imidazolyl and R4 is selected from the group consisting of hydrogen, hydroxyl, alkyl of 1 to 4 carbon atoms, phenyl and benzyl with the proviso that when R1 is in the 7 or 8-position and is halogen, --CH3, --OCF3 or --SCF3 and R4 is hydrogen, R3 is not thiazolyl, pyridinyl or oxazolyl and the non-toxic, pharmaceutically acceptable acid addition salts when R3 is imidazolyl or 4,5-dihydrothiazolyl having analgesic activity and their preparation and novel intermediates therefore.